Substituted Indole Ether Compounds for TLR Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases related to Toll-like receptor 7, 8, and 9 (TLR7, TLR8, TLR9) modulation are inadequate in terms of stability, bioavailability, and therapeutic index, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of substituted indole ether compounds that act as inhibitors of TLR7, TLR8, and TLR9 signaling, formulated into pharmaceutical compositions for effective treatment of proliferative, allergic, autoimmune, and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then TLR modulation is achieved, but stability, bioavailability, and therapeutic index are inadequate
Solution Approach 1:
The patent modifies the chemical structure of TLR modulators by introducing specific substituents at defined positions (e.g., R1, R2, R3, R4, R5, R6 groups) to optimize the balance between therapeutic effectiveness, stability, and bioavailability. These structural parameter changes create compounds with improved pharmacological properties while maintaining TLR modulation activity.
Solution Approach 2:
The invention develops composite molecular structures combining indole core with various heterocyclic groups and substituent patterns, creating multifunctional compounds that simultaneously achieve TLR modulation, enhanced stability, and improved bioavailability. The composite structure integrates multiple functional elements working synergistically.
2Reliability
If current TLR modulating compounds are used, then some therapeutic benefit is achieved, but bioavailability is insufficient
Solution Approach 1:
The patent optimizes bioavailability by carefully selecting and positioning specific chemical groups (e.g., heterocyclic rings, alkyl chains, aromatic substituents) that enhance membrane permeability, metabolic stability, and protein binding characteristics. These parameter modifications directly improve the compound's ability to reach target tissues at effective concentrations.
3Object-affected harmful factors
If current TLR modulating compounds are used, then inflammatory responses are modulated, but therapeutic index is suboptimal
Solution Approach 1:
The patent introduces specific functional groups and substituent patterns at particular positions on the molecular scaffold to enhance selective binding to TLR7/8/9 while minimizing off-target effects. This local optimization of molecular properties improves the therapeutic index by increasing specificity for the intended target and reducing systemic toxicity.
Solution Approach 2:
The invention modifies key molecular parameters including lipophilicity, molecular weight, and hydrogen bonding capacity to optimize the balance between anti-inflammatory efficacy and safety profile. These parameter adjustments create compounds with improved therapeutic windows.
Data Source
AI summary
Disclosed are compounds of Formula (I) (I) N-oxides, or salts thereof, wherein R1, G, A, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.